Navigation Links
China Medicine Corporation to Restate Financial Statements for 2006 and 2007
Date:7/8/2011

GUANGZHOU, China, July 8, 2011 /PRNewswire-Asia/ -- China Medicine Corporation (Other OTC: CHME) (the "Company"), a leading manufacturer, developer and distributor of Western pharmaceuticals, traditional Chinese medicines ("TCM"), and other health products in the People's Republic of China, today announced that the Board of Directors (the "Board") of China Medicine Corporation, after consultation with and upon the recommendation of the management of the Company and the Audit Committee of the Board (the "Audit Committee"), concluded that the Company's previously issued financial statements contained in the Company's Annual Report on Form 10-K for the fiscal years ended December 31, 2006 and 2007, and the Quarterly Reports on Form 10-Q for the periods within the fiscal years 2006 and 2007 (collectively, "the previously issued financial statements") should no longer be relied upon.  

As previously disclosed in the Company's Form 8-K filed with the Securities and Exchange Commission on March 23, 2011, the Board, concluded that the Company's previously issued financial statements contained in the Company's Annual Report on Form 10-K for the fiscal years ended December 31, 2008 and 2009, and the Quarterly Reports on Form 10-Q for the periods within the fiscal years 2008, 2009 and 2010 should no longer be relied upon.

On July 1, 2011, during the course of the on-going internal reviews by the management and the Audit Committee of the Company, the Board determined that the accounting and reporting errors at Guangzhou Konzern Medicine Co., Ltd., a wholly-owned subsidiary of the Company, also occurred in fiscal years 2006 and 2007 in addition to fiscal years 2008, 2009 and the quarterly periods in fiscal year 2010, as previously reported, and such errors materially impacted the previously issued financial statements.  The Company currently is not able to and will not be able to quantify the impact of these errors and related accounting adjustments until the completion of its internal reviews but has concluded that the previously issued financial statements should no longer be relied upon. The Company anticipates that at the conclusion of the internal review by the Audit Committee and its legal counsel, with the assistance of Ernst & Young Advisory Services Limited, and the completion of a re-audit of the affected fiscal years, it will have revised financial results and will issue restated financial statements.

Management is assessing what changes may be necessary in the evaluation of the Company's internal control over financial reporting and its disclosure controls and procedures and will not reach a final conclusion with respect to these matters until completion of the restatement process.

As soon as practicable, in addition to the previously disclosed amendments, the Company expects to file amendments to its Annual Report on Form 10-K for the years ended December 31, 2006 and 2007, and amendments to its Quarterly Reports on Form 10-Q for the periods within fiscal years 2006 and 2007 reflecting the restated financial statements with respect to the previously issued financial statements.  Given that the review process is still ongoing, the matters discussed herein are preliminary and subject to change. 

About China Medicine Corporation

China Medicine Corporation, a vertically integrated enterprise with a research and development center, manufacturing facility and well established sales network, engages in the production and distribution of prescription and over the counter drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The Company is developing a number of proprietary products for a variety of indications, including oncology, high blood pressure and toxin removal from food and animal feeds. For more information, please visit the Company's website at http://www.cmc621.com.  The Company routinely posts important information on its website.

Safe-Harbor Statement

This press release contains forward-looking statements concerning the Company's business and products. The Company's actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this cautionary statement and the risk factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statement to reflect events or circumstances after the date of this release.

Contact Information

ICR, Inc.
In New York: Ms. Christine Duan: 1-203-682-8200
In Beijing: Ms. Wen Lei Zheng: 86-10-6599-7968


'/>"/>
SOURCE China Medicine Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lithotripters Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017
2. China Botanic Pharmaceutical Granted China Patent for Siberian Ginseng Extraction Process
3. China Grants COPAN Patent for Flocked Swabs
4. Golden Meditech to Increase Stake in NYSE-listed Affiliate -- China Cord Blood Corporation to 39.5%
5. Reportlinker Adds The Outlook for Medical Devices in Brazil, Russia, India & China
6. Winner Medical to Present at Brean Murray, Carret & Co. Beijing China Growth Conference
7. China Medical Technologies Announces Strategic Collaboration Between its Subsidiary, GP Medical, and Da An Health
8. Chinmax Disclaims Liability Following China SFDAs Confirmation that Inverness Medical Beijing is Suspected of Forging SFDA Verification Seal and Approval Date in Submission of Triage BNP Test Registration
9. Nutrastar to Participate in Brean Murray, Carret & Co.s 2011 Beijing China Growth Conference
10. Access Pharmaceuticals Receives Letter of Acceptance For MuGard Filing From SFDA of China
11. China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):